METHODS	Twenty-six hospitalized treatment-resistant patients with chronic DSM-IV-diagnosed schizophrenia participated in a randomized , double-blind , placebo-controlled trial in which 300 mg/day of topiramate was gradually added to their ongoing treatment ( clozapine , olanzapine , risperidone , or quetiapine ) over two 12-week crossover treatment periods .\